alexa Phospho-TCTP and Dihydroartemisinin: A Novel Therapeuti
ISSN: 2167-7700

Chemotherapy: Open Access
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Commentary

Phospho-TCTP and Dihydroartemisinin: A Novel Therapeutic Opportunity in Advance Breast Cancer

Maria Lucibello1* and Filippo De Braud2

1Institute of Translational Pharmacology, National Research Council, Rome, Italy

2Medical Oncology Department, Pathology and Molecular Biology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

*Corresponding Author:
Maria Lucibello
Institute of Translational Pharmacology
National Research Council, Rome, Italy
Tel: +39 06 45488002
E-mail: [email protected]

Received date: December 29, 2015 Accepted date: March 01, 2016 Published date: March 07, 2016

Citation: Lucibello M, De Braud F (2016) Phospho-TCTP and Dihydroartemisinin: A Novel Therapeutic Opportunity in Advance Breast Cancer. Chemo Open Access 5:196. doi:10.4172/2167-7700.1000196

Copyright: © 2016 Lucibello M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

The development of resistance to chemotherapeutics is still a severe event in cancer patients. One of the major obstacles to the effectiveness of cancer therapies is the development of side effects and resistance to therapy. The characterization of novel biomarkers that support a more aggressive phenotype may provide new diagnostic tools and new opportunities for cancer therapy. In the context of breast cancer disease, the phosphorylated form of Translationally controlled tumor protein (phospho-TCTP) appears a new prognostic factor for aggressive breast cancer and tumor progression. Dihydroartemisinin (DHA) is a novel approach to molecular targeted therapies, or combination regimens in advance breast cancer.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords